[Pharmacokinetics (PK) of mAbs]

Area of Science:

• Pharmacology
• Immunology
• Biochemistry

Background:

• Humanized monoclonal antibodies (mAbs) possess extended serum half-lives, comparable to endogenous immunoglobulin G (IgG), primarily due to their Fc region.
• The neonatal Fc receptor (FcRn) is a critical determinant of mAb pharmacokinetics (PK), influencing their stability, absorption, and distribution.

Purpose of the Study:

• To elucidate the multifaceted role of FcRn in mAb pharmacokinetics, including its impact on half-life, absorption, distribution, and elimination.
• To explore the tissue distribution of mAbs and the potential protective role of FcRn in specific organs like the central nervous system.
• To investigate the factors contributing to interindividual variability in mAb PK and the necessity for sophisticated PK modeling.

Main Methods:

• Review of existing literature on mAb pharmacokinetics and FcRn interactions.
• Analysis of data regarding mAb absorption, distribution, and elimination pathways.
• Examination of factors influencing mAb PK variability, such as demographic characteristics and antigen binding.

Main Results:

• FcRn binding confers long half-lives to mAbs by preventing degradation and facilitates transcytosis, impacting absorption and distribution.
• Subcutaneous absorption of mAbs is often slow and incomplete, leading to prevalent intravenous administration.
• mAb tissue distribution is generally limited, with potential FcRn-mediated protection of the central nervous system; elimination is partly target-mediated, causing dose-dependent PK.

Conclusions:

• FcRn significantly governs mAb pharmacokinetics, affecting their therapeutic efficacy and dosing strategies.
• Interindividual variability in mAb PK, influenced by demographic factors, antigen load, and immunization status, necessitates complex PK models for accurate prediction.
• Further research into mAb distribution and FcRn interactions is essential for optimizing therapeutic applications.